ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells

Cell Death and Differentiation

Volumn 20, Issue 4, 2013, Pages 525-534

  Wang, Y ^a   Godin Heymann, N ^a,b   Dan Wang, X ^a,c   Bergamaschi, D ^a,d   Llanos, S ^a   Lu, X ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; ASPP1; ASPP2; P53; RAS

Indexed keywords

APOPTOSIS STIMULATING PROTEIN OF P53 1; APOPTOSIS STIMULATING PROTEIN OF P53 2; PROTEIN; PROTEIN P53; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE; HUMANS; MCF-7 CELLS; MICE; PROTEIN BINDING; RAS PROTEINS; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874949078     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.3     Document Type: Article

References (40)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev 2003; 3: 11-22.
2. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta 2008; 1786: 178-187.
3. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011; 8: 492-503.
4. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.
5. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003; 22: 8999-9006.
6. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998; 395: 125-126.
7. Zindy F, Eischen C, Randle D, Kamijo T, Cleveland J, Sherr C et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-2433.
8. de Stanchina E, McCurrach ME, Zindy F, Shieh S-Y, Ferbeyre G, Samuelson AV et al. E1A signaling to p53 involves the p19ARF tumour suppressor. Genes Dev 1998; 12: 2434-2442.
9. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
10. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1: 20-26.
11. Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999; 18: 4974-4982.
12. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
13. Wang Y, Wang XD, Lapi E, Sullivan A, Jia W, He YW et al. Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci USA 2012; 109: 13325-13330.
14. Wang XD, Lapi E, Sullivan A, Ratnayaka I, Goldin R, Hay R et al. SUMO-modified nuclear cyclin D1 bypasses Ras-induced senescence. Cell Death Differ 2011; 18: 304-314.
15. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol 2004; 24: 1341-1350.
16. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-794.
17. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, Hsieh JK et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 2003; 33: 162-167.
18. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006; 38: 1133-1141.
19. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 1997; 11: 1840-1852.
20. Fogal V, Kartasheva NN, Trigiante G, Llanos S, Yap D, Vousden KH et al. ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ 2005; 12: 369-376.
21. Cong W, Hirose T, Harita Y, Yamashita A, Mizuno K, Hirano H et al. ASPP2 regulates epithelial cell polarity through the PAR complex. Curr Biol 2010; 20: 1408-1414.
22. Sottocornola R, Royer C, Vives V, Tordella L, Zhong S, Wang Y et al. ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell 2010; 19: 126-137.
23. Tidow H, Andreeva A, Rutherford TJ, Fersht AR. Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a ubiquitin-like fold. J Mol Biol 2007; 371: 948-958.
24. Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010; 29: 4658-4670.
25. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA. Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation. Oncogene 2002; 21: 1527-1538.
26. Naumovski L, Cleary ML. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol Cell Biol 1996; 16: 3884-3892.
27. Vigneron AM, Ludwig RL, Vousden KH. Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev 2010; 24: 2430-2439.
28. Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X et al. The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev 2010; 24: 2420-2429.
29. Hirashima M, Sano K, Morisada T, Murakami K, Rossant J, Suda T. Lymphatic vessel assembly is impaired in Aspp1-deficient mouse embryos. Dev Biol 2008; 316: 149-159.
30. Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev 2006; 20: 1262-1267.
31. Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K et al. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci USA 2009; 106: 4390-4395.
32. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997; 385: 544-548.
33. Navarro P, Valverde AM, Benito M, Lorenzo M. Activated Ha-ras induces apoptosis by association with phosphorylated Bcl-2 in a mitogen-activated protein kinase-independent manner. J Biol Chem 1999; 274: 18857-18863.
34. Fukasawa K, Vande Woude GF. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 1997; 17: 506-518.
35. Vater CA, Bartle LM, Dionne CA, Littlewood TD, Goldmacher VS. Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts. Oncogene 1996; 13: 739-748.
36. Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW, Deichman GI et al. p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996; 13: 1709-1719.
37. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659.
38. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
39. Ferbeyre G, de Stanchina E, Querido E, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14: 2015-2027.
40. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998; 17: 5001-5014.